According to recent findings, PARP inhibitors promote the buildup of cytosolic fragments of DNA as a result of unsolved DNA lesions, further activate the DNA-sensing cGAS-STING pathway which results in stimulating type I interferon production to further stimulate anti-tumor immunity which is independent of BRCA status (Shen et al., 2019). Here, PARP1 is linked to neoplasm.